Formulary
Enzalutamide: Indications, Dosing, Side Effects and Interactions
Enzalutamide clinical drug profile including indications, dosing, side effects, cautions and interactions.
MedNext Academy | 3 min read
Enzalutamide: Indications, Dosing, Side Effects and Interactions
Enzalutamide clinical drug profile including indications, dosing, side effects, cautions and interactions.
Indications and dose
**Prostate cancer (specialist use only)**
- **Adult** (By Mouth): 160 mg once daily, for dose adjustments due to side-effects-consult product literature.
Cautions
History or risk of QT-interval prolongation; history or risk of seizure; recent cardiovascular disease
Side effects
Common or very common Acute coronary syndrome; anxiety; asthenia; atherosclerosis coronary artery; bone fracture; concentration impaired; fall; gynaecomastia; headache; hot flush; hypertension; ischaemic heart disease; memory loss; restless legs; skin reactions; taste altered Uncommon Cognitive disorder; leucopenia; neutropenia; seizures; visual hallucinations Frequency not known Back pain; diarrhoea; face oedema; muscle complaints; muscle weakness; nausea; oral disorders; posterior reversible encephalopathy syndrome (PRES); QT interval prolongation; second primary malignancy; severe cutaneous adverse reactions (SCARs); throat oedema; thrombocytopenia; vomiting
Interactions
**Severe interactions:**
- Effect of food on enzalutamide exposures Food has no clinically significant effect on the extent of exposure to enzalutamide.
**Other interactions (35):**
- Potential for other medicinal products to affect enzalutamide exposures CYP2C8 inhibitors CYP2C8 plays an important role in the elimination of enzalutamide and in the formation of its active...
- Following oral administration of the strong CYP2C8 inhibitor gemfibrozil (600 mg twice daily) to healthy male subjects, the AUC of enzalutamide increased by 326% while C max of enzalutamide...
- For the sum of unbound enzalutamide plus the unbound active metabolite, the AUC increased by 77% while C max decreased by 19%.
- Strong inhibitors (e.g.
- If patients must be coadministered a strong CYP2C8 inhibitor, the dose of enzalutamide should be reduced to 80 mg once daily (see section 4.2).
- CYP3A4 inhibitors CYP3A4 plays a minor role in the metabolism of enzalutamide.
Renal impairment
Caution in severe impairment and end-stage renal disease-no information available. M
Medicinal forms
Clinical governance
**Author:** MedNext Clinical Team. **Clinical reviewer:** Dr Shameer Deen, MBBS, MS, MRCS. **Sources:** BNF, Indian Pharmacopoeia, CIMS India. **Correction:** Report errors at support@mednext.academy.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- Growing visual cheat sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Subject HubPharmacology Hub
All pharmacology resources in one place.
Drug SchedulesIndian Drug Schedules
Schedule H, H1, X and G classifications.
FormularyBrowse all drugs
Search 1,850+ drug profiles.
Study Enzalutamide in the MedNext app
Challenge yourself with targeted pharmacology MCQs on this drug class. Every explanation links back to the chapter that teaches the concept.
Start drug challengeExplore the full formulary

